Ortho Clinical Diagnostics (NASDAQ:OCDX) Earns Overweight Rating from Analysts at Piper Sandler

Piper Sandler began coverage on shares of Ortho Clinical Diagnostics (NASDAQ:OCDX) in a research note published on Monday morning, The Fly reports. The firm issued an overweight rating on the stock.

A number of other research analysts also recently issued reports on OCDX. UBS Group started coverage on shares of Ortho Clinical Diagnostics in a research report on Monday. They set a buy rating and a $23.00 target price on the stock. Credit Suisse Group began coverage on shares of Ortho Clinical Diagnostics in a research note on Monday. They issued an outperform rating and a $21.00 price objective on the stock. Bank of America assumed coverage on shares of Ortho Clinical Diagnostics in a research report on Monday. They set a buy rating and a $23.00 target price for the company. Citigroup assumed coverage on Ortho Clinical Diagnostics in a research report on Monday. They issued a buy rating and a $20.00 price target on the stock. Finally, Morgan Stanley started coverage on Ortho Clinical Diagnostics in a research note on Monday. They set an overweight rating and a $24.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $24.00.

Shares of OCDX opened at $17.11 on Monday. Ortho Clinical Diagnostics has a 12-month low of $15.14 and a 12-month high of $18.65.

About Ortho Clinical Diagnostics

Ortho Clinical Diagnostics Holdings plc engages in the vitro diagnostics business in the United States. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a broad spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases.

Featured Article: QQQ ETF

The Fly

Analyst Recommendations for Ortho Clinical Diagnostics (NASDAQ:OCDX)

Receive News & Ratings for Ortho Clinical Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ortho Clinical Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.